FMN2 and colorectal carcinoma: Nevertheless, few studies have been reported on FMN2 (T: 7.91% and V: 16.98%), TRRAP (T: 10.73% and V: 9.43%) and ATR (T: 5.08% and V: 9.43%) in CRC patients.